Using genome sequencing and digital twins to manage high cholesterol in Emiratis
Official title: A Randomized Trial of Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia in Emiratis
Run by Abu Dhabi Health Services Company · NCT06535542 · Data updated 2026-11-12
This study is testing if using genetic information and digital twin technology can help Emirati patients with high cholesterol get better personalized treatment and manage their condition more effectively.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 55 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Abu Dhabi Health Services Company Government |
| Locations | 1 site (Abu Dhabi, Abu Dhabi Emirate) |
| Status | Recruiting |
| Started | July 29, 2024 |
| Main results expected | December 15, 2025 |
| Study ends | July 15, 2026 |
| Registry record updated | March 25, 2025 |
| Trial ID | NCT06535542 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include Emirati nationals aged 18-55 with high LDL-C levels and undiagnosed familial hypercholesterolemia.
✕Probably not a fit
Patients with a previous diagnosis of familial hypercholesterolemia or those with certain untreated medical conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This pilot study explores the integration of whole genome sequencing and digital twin technology to improve the management of hypercholesterolemia among Emirati patients. It aims to establish protocols for future larger studies by incorporating genomic insights into routine medical care. The study focuses on understanding the genetic mechanisms of hypercholesterolemia, particularly in patients who may not have identifiable mutations. By leveraging digital twin technology, the study seeks to personalize treatment plans and enhance patient adherence to cholesterol management.
Why it matters
Potential benefit: If successful, this approach could lead to more effective management of hypercholesterolemia, reducing cardiovascular risks for patients.
How similar studies have gone: While the integration of genome sequencing and digital twins is innovative, similar approaches in other populations have shown promise, indicating potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with 2 or more LDL-C levels greater than 190 mg/dL or 5.0 mmol/L in the past 12 months * Undiagnosed patients meeting Possible, Probable or Definitive FH criteria according to Dutch Lipid Clinic Network (DLCN) criteria (Eur Heart J. 2011 Jul;32(14):1769-818. doi: 10.1093/eurheartj/ehr158. Epub 2011 Jun 28.) * Patients who have not been on anti-lipidemic medication in the past 3 months * Ages 18-55 * Emirati national * All patients must be fluent in English or Arabic Exclusion Criteria: * \- Patients who do not meet the above criteria * Patients with a previous diagnosis of FH * Patients with a progressive debilitating illness * Patient with untreated hypothyroidism, history of proteinuria, obstructive liver disease, chronic renal failure, human immunodeficiency virus infection, or on immunosuppressant or steroid or psychiatric medications * Patients with untreated clinical anxiety or depression (as measured by a Hospital Anxiety and Depression Scale (HADS) score of ≥ 16 on the depression subscale) * Patients who are pregnant
Where it's running
-
Abu Dhabi Health Research Center
Abu Dhabi, Abu Dhabi Emirate, United Arab Emirates Recruiting
Study contacts
- Principal investigator: Abdulmajeed BS Alzubaidi, MD — Abu Dhabi Health Services Co. -SEHA
- Study coordinator: Alina Naeem, MBBS
- Email: alnaeem@seha.ae
- Phone: +97124102534
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effect of Gum Arabic on Kidney Function in Dialysis Patients
This study is testing if adding Gum Arabic to the treatment of dialysis patients with kidney failure can improve their kidney function and overall health.
-
Examining outcomes in STEMI patients with cardiogenic shock in Abu Dhabi
This study looks at the health outcomes of patients in Abu Dhabi who had a serious heart attack complicated by shock to see how different treatments and patient factors affect their recovery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.